| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers Tenders > Headlines for 2004 > News item |
CV Therapeutics buybacks of 4.75% convertibles now total $116.6 million
New York, Aug. 9 - CV Therapeutics Inc. said it bought back a total of $116.6 million of 4.75% convertible subordinated notes due 2007 during May and June.
The repurchases left $79.6 million of the issue outstanding as of June 30, according to a 10-Q filing with the Securities and Exchange Commission.
The Palo Alto, Calif.-based biotechnology company previously reported $101.6 million of buybacks.
In total, CV Therapeutics recorded a loss of $3.3 million for the early extinguishment of debt, which included $1.6 million in unamortized offering costs and $1.7 million in premium payments above the principal value of the notes.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.